0.4939
Medicus Pharma Ltd (MDCX) 最新ニュース
Medicus Biosciences—Biotech Company Focused on Innovative Microneedle Technology and Global Patent Portfolio - Minichart
Medicus Pharma Advances SkinJect and Teverelix Pipelines, Adds AI to Clinical Strategy - TipRanks
Medicus Pharma Ltd reports results for the quarter ended December 31Earnings Summary - TradingView
Medicus Pharma (NASDAQ: MDCX) registers 3.245M common shares from warrants - Stock Titan
Medicus Pharma (MDCX) 1.12M shares issuable on warrants — prospectus supplement - Stock Titan
Medicus Pharma (MDCX) registers 2.26M shares tied to public warrants - Stock Titan
1.397M resale shares registered as Medicus Pharma (NASDAQ: MDCX) shifts S-1 to S-3 - Stock Titan
[POS AM] Medicus Pharma Ltd. S... - Stock Titan
Medicus Pharma Reports Full-Year 2025 Financial Results and Provides Corporate Update - ACCESS Newswire
Biotech says 3 in 4 patients may avoid immediate skin cancer surgery - Stock Titan
Medicus Pharma 2025 10-K: Net loss $35.4M, EPS $(2.74) - TradingView
Medicus Pharma to host business update call featuring clinical investigator - MSN
Medicus Pharma on Bloomberg World - Daytona Beach News-Journal
Medicus Pharma to Host Business Update Call Featuring Clinical Investigator - MyChesCo
Medicus Pharma reports phase 2 results for basal cell carcinoma therapy - MSN
Medicus Pharma stock swings after skin cancer treatment results - MSN
Tangible book value per share of Medicus Pharma Ltd. – NASDAQ:MDCXW - TradingView
Book value per share of Medicus Pharma Ltd. – NASDAQ:MDCXW - TradingView
Whats next for Medicus Pharma Ltd Equity Warrant stock2026 Technical Overview & Precise Swing Trade Alerts - baoquankhu1.vn
Medicus reports phase 2 results for SkinJect basal cell carcinoma study - MSN
Medicus Pharma Ltd expected to post a loss of 15 cents a shareEarnings Preview - TradingView
Analyst Calls: Is Medicus Pharma Ltd exposed to currency risks2026 Price Swings & Technical Entry and Exit Tips - baoquankhu1.vn
Medicus Pharma to host fireside chat on SkinJect trial results By Investing.com - Investing.com South Africa
MDCXW Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Will Medicus Pharma Ltd outperform the market in YEARDividend Hike & Advanced Swing Trade Entry Alerts - baoquankhu1.vn
Medicus Pharma prices $7 million share offering - MSN
Medicus Pharma Showcases Strong Phase 2 SkinJect Data Ahead of Fireside Chat - TipRanks
Medicus Pharma to host fireside chat on SkinJect trial results - Investing.com
Medicus Pharma To Discuss Positive Skinject(R) Phase 2 Topline Results In Fireside Chat Hosted By Brookline Capital Markets Biotechnology Equity Research Analyst - ACCESS Newswire
Medicus Pharma (MDCX) FDA Approvals, PDUFA Dates & Drug Alerts 2026 - MarketBeat
Aug Sectors: What is the dividend yield of Medicus Pharma Ltd Equity Warrant2026 Sector Moves & High Accuracy Trade Signal Alerts - baoquankhu1.vn
Medicus Pharma schedules webcast on basal cell carcinoma study By Investing.com - Investing.com Australia
Aug Opening: Is Medicus Pharma Ltd Equity Warrant a speculative investment2026 Volume & Daily Risk Controlled Trade Plans - baoquankhu1.vn
Investment Recap: Can Medicus Pharma Ltd sustain its profitabilityTrade Exit Report & Technical Entry and Exit Tips - baoquankhu1.vn
Medicus Pharma to highlight positive Phase 2 SkinJect data during webcast with lead investigator - Proactive financial news
Medicus Pharma Highlights Strong Phase 2 SkinJect Data Ahead of Business Update Call - TipRanks
Medicus Pharma schedules webcast on basal cell carcinoma study - Investing.com
Medicus Pharma Announces SkinJect® Phase 2 Principal Investigator and Key Opinion Leader (KOL), Babar K. Rao MD, FAAD, to Provide Clinical Interpretation of Positive Data During Business Update Webcast on March 26 - ChartMill
Medicus Reports Phase 2 Results for SkinJect Basal Cell Carcinoma Study - MyChesCo
Medicus Pharma CEO discusses promising Phase 2 SkinJect resultsICYMI - Proactive financial news
Medicus Pharma Marks Nasdaq Anniversary with Opening Bell Ceremony - The Globe and Mail
Medicus Pharma reports positive phase 2 results for SkinJect skin cancer therapy - MSN
Risk Report: Will Medicus Pharma Ltd outperform the market in YEAR2026 Update & High Accuracy Investment Signals - baoquankhu1.vn
大文字化:
|
ボリューム (24 時間):